Virax Biolabs Group Limited Ordinary Shares
Symbol: VRAX (NASDAQ)
0.59
▼ (-0.68%) -0.004
Company Description:
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).
Key Stats
- Today's Open: $0.6053
- Today's High: $0.624
- Today's Low: $0.577
- Today's Volume: 89.32K
- Yesterday Close: $0.59
- Yesterday High: $0.62
- Yesterday Low: $0.59
- Yesterday Volume: 60.97K
- Last Min Volume: 2
- Last Min High: $0.586
- Last Min Low: $0.586
- Last Min VWAP: $0.586
Company Profile
- Name: Virax Biolabs Group Limited Ordinary Shares
- Website: https://www.viraxbiolabs.com
- Listed Date: 2022-07-21
- Location: ,
- Market Status: Active
- CIK Number: 0001885827
- SIC Code:
- SIC description:
- Market Cap: $2.54M
- Round Lot: 100
- Outstanding Shares: 4.34M
- Asset Type: CS
RECENT FILINGS FOR VRAX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-07-30 | 6-K | View |
| 2025-07-02 | 20-F | View |
| 2025-06-13 | 6-K | View |
| 2025-03-18 | 6-K | View |
| 2025-03-13 | 6-K | View |
| 2025-03-05 | 6-K | View |
| 2025-02-25 | 6-K | View |
| 2025-01-30 | S-8 | View |
| 2024-12-23 | 6-K | View |
| 2024-12-17 | 6-K | View |
| 2024-12-10 | 6-K | View |
| 2024-11-20 | 6-K | View |
| 2024-11-14 | SC 13G/A | View |
| 2024-10-31 | 6-K | View |
| 2024-10-23 | 6-K | View |
| 2024-09-30 | 6-K | View |
| 2024-09-30 | 424B5 | View |
| 2024-08-23 | 6-K | View |
| 2024-08-23 | 424B5 | View |
| 2024-08-20 | 20-F | View |
Latest News on VRAX